Next Article in Journal
Research on Supply Chain Network Resilience: Considering Risk Propagation and Node Type
Previous Article in Journal
Activity and Dose Rate Calculations for Joint European Torus Outer Long-Term Irradiation Station during Tritium and Second Deuterium Tritium Experiment Campaigns
Previous Article in Special Issue
Species Diversity, Nitrogen Fixation, and Nutrient Solubilization Activities of Endophytic Bacteria in Pea Embryos
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Applied Sciences
Volume 14
Issue 7
10.3390/app14072676
applsci-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Antifungal Effect of Weissella confusa WIKIM51 (Wilac D001) on Vaginal Epithelial Cells Infected by Candida albicans

by
Gain Lee
1,2,
Young-Ah You
2,
Abuzar Ansari
2,
Yoon-Young Go
2,
Sunwha Park
2,
Young Min Hur
2,
Soo-Min Kim
1,
Sang Min Park
3 and
Young Ju Kim
1,2,*
1
Graduate Program in System Health Science and Engineering, Ewha Womans University, Seoul 03760, Republic of Korea
2
Department of Obstetrics and Gynecology, Ewha Medical Research Institute, College of Medicine, Ewha Womans University, Seoul 07984, Republic of Korea
3
Pharmsville Co., Ltd., Seoul 06642, Republic of Korea
*
Author to whom correspondence should be addressed.
Appl. Sci. 2024, 14(7), 2676; https://doi.org/10.3390/app14072676
Submission received: 4 January 2024 / Revised: 9 March 2024 / Accepted: 15 March 2024 / Published: 22 March 2024
(This article belongs to the Special Issue Feature Review Paper in "Applied Microbiology" Section)
Browse Figures
Review Reports Versions Notes

Abstract

:
Vulvovaginal candidiasis (VVC) is a genital infection caused by Candida albicans (C. albicans). Weissella confusa WIKIM51 (Wilac D001) is known to be detected in dandelion kimchi, produce lactic acid, and have an anti−inflammatory ability; however, its diverse antifungal effects have not been studied. Here, we investigated the antifungal effect of Wilac D001 in C. albicans compared to Lactobacillus species on vaginal epithelial cells (VECs). To test the antifungal ability of Wilac D001 against C. albicans on VECs, an adhesion test, pro-inflammatory cytokines (interleukin (IL)-6 and IL-8) analysis, and a disk diffusion test were performed. The acid tolerance test was conducted to investigate the viability of Wilac D001 in various acidic conditions. Lactobacillus reuteri (L. reuteri) and L. rhamnosus were used as positive controls. Wilac D001 showed the capacity to inhibit the colonization of C. albicans by adhering to VECs, with an inhibitory effect similar to that of positive controls. Both pro−inflammatory cytokines including IL−6 and IL−8 concentrations were significantly decreased when Wilac D001 was treated on C. albicans-infected VECs, respectively (p < 0.001). The result of the disk diffusion test indicates that the inhibitory ability of Wilac D001 is comparable to L. reuteri and L. rhamnosus on agar plates infected with C. albicans. Our results demonstrate that Weissella confusa WIKIM51 has antifungal effects against VECs infected by C. albicans.

1. Introduction

Vulvovaginal candidiasis (VVC), caused by Candida species, is the second most common fungal infection of the genital tract [1]. Candida albicans (C. albicans), the major etiologic agent of VVC, is present, with a prevalence of up to 78% [2,3]. The onset of VVC is mostly associated with the use of antibiotics, lack of Lactobacillus spp. in the vagina, sexual activity, and use of hygiene products [2,4]. The common symptoms of VVC include itching, burning, and redness [5].
Antibiotic therapy is an effective clinical strategy for controlling C. albicans infection. However, the continuous use of antibiotics can increase drug resistance, relapse rates, and interrupt the composition of vaginal microbiota [6,7]. Recent in vitro and in vivo studies have demonstrated lactobacilli-mediated immune defense against C. albicans colonization [8,9]. Thus, interest in the development of alternative strategies that involve indirect treatment of VVC using lactobacilli has increased.
Lactobacillus species represent the predominant bacterial group in healthy vaginas. Lactobacillus species are a major source of lactic acid and bacteriocins that maintain the vaginal microflora in an acidic environment, contributing to reducing the invasion of pathogenic infections by competing to the adhesion site [10,11]. Moreover, these vaginal lactobacilli regulate the innate immune system through controlling the secretion of cytokines and antibody responses against pathogenic infections [12]. Prior in vivo and in vitro studies on Lactobacillus spp. have reported that L. reuteri and L. rhamnosus can modulate inflammatory immune responses to counteract against C. albicans [13,14,15].
The Weissella was separated from Lactobacillus and categorized as a genus in 1993 [16]. Weissella confusa WIKIM51 (Wilac D001) was isolated from dandelion kimchi, a traditional Korean fermented food [17]. Several studies have revealed that Weissella confusa produces diverse components such as lactic acid, exopolysaccharide (EPS), and bacteriocin, which facilitate anti-inflammatory and antioxidant activities in the colon [18,19,20]. Moreover, Weissella-abundant women deliver at full term in bacteriodes-dominated communities [21]. The oral administration of Weissella into mice showed that the abundances of Lactobaillus species were increased and modulated regulatory T cells [22,23]. However, the antifungal effect of Wilac D001 has not been fully explored in comparison with Lactobacillus spp. in the vagina. In this study, we examined the antifungal efficacy of Wilac D001 against C. albicans infection in vaginal epithelial cells (VECs) and compared it with that of L. reuteri and L. rhamnosus.

2. Materials and Methods

2.1. Fungal and Bacterial Strains

The pathogenic yeast C. albicans was purchased from the Korean Collection of Type Cultures (Seoul, Republic of Korea; KCTC7270). The C. albicans was cultured using yeast malt (YM) broth medium (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) under the aerobic condition for 24 h at 30 °C [24].
Bacterial strains, including Weissella confusa WIKIM51 (Wilac D001), L. reuteri (RC−14), and L. rhamnosus (GR−1), were supplied by Pharms Ville (Seoul, Republic of Korea). In this study, L. rhamnosus and L. reuteri were considered positive controls. De Man, Rogosa, and Sharpe (MRS) broth (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) were used to culture bacteria, including Wilac D001 and the positive controls. The bacterial strains were cultured under the conditions described in Supplementary Table S1.

2.2. Culture of Vaginal Epithelial Cell

The vaginal epithelial cell line (VK2/E6E7, CRL−2616) was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). The VECs were cultured in collagen (Sigma, St. Louis, MO, USA)-coated 75 cm2 cell culture flasks using keratinocyte-serum-free medium (K-SFM; GIBCO-BRL San Giuliano Milanese, Milan, Italy) supplemented with components provided by the manufacturer. Finally, the media supplemented with 0.4 mM CaCl2 (Sigma, St. Louis, MO, USA) and 500 UI/mL penicillin (Sigma, St. Louis, MO, USA) were used. The VECs were maintained at 37 °C in a 5% CO2 incubator. The culture medium was replaced every 2−3 days, and cell viability was assessed using trypan blue dye (Sigma, MO, USA) and a hemocytometer (Paul Marienfeld GmbH & Co. KG, Lauda-Königshofen, Gemany).

2.3. Adhesion Test

Adhesion tests were conducted following a previously standardized method [25]. For this assay, a sterilized cover glass was placed in each well of a 6−well plate to facilitate the observation of morphological changes in VECs using a light microscope (BX41; Olympus, Japan). Wilac D001 and C. albicans (1 × 107 CFU/mL) were added to VECs, followed by their incubation for 1 h. Subsequently, a Gram staining (Sigma) assay was performed, and the frequency of adherent cells was calculated [26]. The number of adherent VECs was determined for 30 consecutive cells in each replication [27]. The percentage of adherent cells (%) was calculated using the following formula:
A d h e r e n t   C e l l   % = V E C s   a t t a c h e d   b a c t e r i a   w i t h o u t   C .   a l b i c a n s T o t a l   c e l l s × 100

2.4. Enzyme-Linked Immunosorbent Assay (ELISA) Analysis

VECs were seeded at a density of 1 × 105 cells/mL in 6-well plates and maintained at 37 °C in a 5% CO2 environment for 96 h. To test whether Wilac D001 can regulate pro−inflammation cytokine, VECs were incubated with C. albicans (1 × 107 CFU/100 µL) for 12 h and sequentially replaced by Wilac D001 (1 × 107 CFU/100 µL) for 24 h. VECs were co−cultured with C. albicans (1 × 107 CFU/100 µL) and maintained for 36 h to induce inflammation [28]. Next, the sample in each well was washed with phosphate-buffered saline (PBS; Biosesang, Gyeonggi-do, Republic of Korea), and 1 × 105 CFU/mL of Wilac D001 was added to it. After co-culturing with Wilac D001 for 24 h, the supernatant of the medium was carefully collected and centrifuged at 5000 rpm to remove cell debris. The expression of IL−6 and IL−8 in the supernatant was quantified using ELISA kits (Abbkine, Atlanta, Georgia, USA) according to the instructions provided by the manufacturer. The concentrations of IL−6 and IL−8 in each supernatant were measured at 450 nm using a microplate reader.

2.5. Disk Diffusion Assay

For the disk diffusion analysis, commonly used to determine the susceptibility of pathogenic microorganisms to antibiotics, the method described by Matevosyan et al. [29] was followed with modifications. C. albicans was cultured using YM broth for 18 h at 30 °C in a shaking condition (100 rpm). Subsequently, C. albicans cultures were washed twice with PBS. A suspension of C. albicans (1 × 105 CFU) was evenly spread on the MRS agar plate and incubated for 3 h at 30 °C. Next, sterile paper disks (diameter: 5 mm) were placed onto the agar plate, and a bacterial suspension of 1 × 107 CFU/25 µL was added to each paper disk, followed by incubation for 24 h at 37 °C. A zone of inhibition (ZoI) was produced around the disk area in which C. albicans did not grow. Sertaconazole nitrate, as antimicrobial agent, was used as a positive control [29].

2.6. Statistical Analysis

Statistical analyses were performed using the SPSS statistical package (version 20.0; SPSS Inc., Armonk, NY, USA). One-way analysis of variance (ANOVA) and Student’s t-test were used to compare the results between different experimental groups and positive controls. All experiments were independently repeated 2 or 3 times. The Shapiro–Wilk test was performed to test normal distribution, and all data were satisfied normality. The statistical significance was considered at a p-value < 0.05.

3. Results

3.1. Protective Effect of Wilac D001 against C. albicans on VECs

We observed the monolayer of VECs after 96 h of incubation (Figure 1A). The detachment of VECs was observed following colonization by C. albicans (Figure 1B). To investigate whether Wilac D001 competitively protects VECs against C. albicans, Wilac D001 and C. albicans were co−cultured for 1 h on VECs (Figure 2A). No significant differences were observed between Wilac D001 and the positive controls (Figure 2B). The VECs were surrounded by Wilac D001, and they showed any colonization by C. albicans (Figure 2E and Figure S1). Similar outcomes were observed during the co−incubation of VECs with C. albicans and the positive control strains L. reuteri and L. rhamnosus (Figure 2C,D).

3.2. The Inhibitory Effect of Pro−Inflammatory Cytokine Production

VECs infected by C. albicans were cultured for 24 h in the presence or absence of Wilac D001. Subsequently, the concentrations of IL−6 and IL−8 were assessed using the ELISA method (Figure 3A). The upregulated IL−6 and IL−8 expression levels in VECs exposed to C. albicans were suppressed up to approximately two-fold after treatment with Wilac D001 (Figure 3B,C). Additionally, L. reuteri reduced IL−6 and IL−8 production in VECs infected with C. albicans (Figure 3D,E). However, the presence of L. rhamnosus did not significantly affect the production of these cytokines (Figure 3F,G).

3.3. Susceptibility of Wilac D001 against C. alibcans

Next, to identify the susceptibility of C. albicans to Wilac D001, the ZoI was measured to estimate the ability of Wilac D001 to inhibit the growth of C. albicans [27]. The antimicrobial agent (Sertaconazole nitrate) and Lactobacillus spp. were used as positive controls in this assay. All bacteria, including Wilac D001, demonstrated a significant antifungal effect compared to the blank disk. The ZoI exhibited by Wilac D001 confirmed its inhibitory effect, which is comparable to that of L. reuteri and L. rhamnosus (Table 1). However, the inhibitory effect of the antibiotic was greater than that of all bacterial strains.

4. Discussion

Our results indicate that Weissella confusa WIKIM51 (Wilac D001) exhibits antifungal activity by inhibiting the formation of C. albicans biofilm. Pro−inflammatory cytokines, including IL−6 and IL−8, were upregulated by C. albicans infection in VECs; however, they were significantly downregulated by Wilac D001. The inhibitory effect of Wilac D001 against the growth of C. albicans was similar to that of L. reuteri and L. rhamnosus. These results propose that the antifungal effects of Wilac D001 against C. albicans are comparable to those of L. reuteri and L. rhamnosus. In particular, Wilac D001 exhibits a significantly higher efficiency in regulating pro−inflammatory cytokines than L. reuteri and L. rhamnosus.
A vaginal environment dominated by Lactobacillus spp. is crucial for protecting the genital tract from opportunistic infections [4]. Lactobacillus produces lactic acid to maintain an acidic environment and inhibits the growth of other microorganisms as well as the influx of pathogens [4,25]. A lack of lactobacilli in the vagina is associated with infections caused by Candida spp., an opportunistic pathogen. Several gynecologic diseases, including pelvic inflammatory disease (PIV), sensitivity to human immunodeficiency virus (HIV), and even adverse pregnancy outcomes, such as the preterm premature rupture of membranes (PPROMs) and preterm birth (PTB), are associated with the proportion of lactobacilli in the vagina [30,31,32].
Here, we have investigated the antifungal effect of Wilac D001, which was isolated from dandelion kimchi, against C. albicans on vascular endothelial cells for the first time. There is concern about the safety of the Weissella genus due to potential pathogenicity [33]. Some studies report that certain strains of W. confusa may cause infections, particularly in immunocompromised patients [34,35]. However, other W. confusa strains show promise in mitigating gut dysbiosis linked to inflammatory bowel disease and cancers, with demonstrated benefits in maintaining intestinal tight junctions and modulating intestinal cell responses [19,35,36]. Therefore, the precise taxonomic category is crucial for understanding its potential pathogenicity. The strain that we used in this experiment is Wilac D001, which is a non−spore−forming, Gram−positive coccobacillus that has obtained safety approval from the FDA. Wilac D001 has been annotated by the National Center for Biotechnology Information (NCBI, CP110106).
The biofilm formation is the essential mechanism underlying C. albicans infection; it enhances pathogenicity through increased colonization and microbial adherence [37]. Adhesion to the surface of the epithelial cell is pivotal to the constant colonization of C. albicans [26,38]. Hyphae−morphological colonization was observed in vaginal epithelial cells infected with C. albicans. However, Wilac D001 protected VECs by blocking the congregation of C. albicans on VECs. Lactobacillus spp. also reduced the adhesion of C. albicans to VECs surfaces by competing for adhesion sites, as reported [39].
The expression of pro−inflammatory cytokines, including IL−6 and IL−8, is upregulated in VECs, owing to C. albicans infection [40]. Furthermore, a clinical study demonstrated that the concentration of IL−8 was higher in women infected with Candida spp. [41]. Our data indicated that Wilac D001 significantly reduced the production of both IL−6 and IL−8 in VECs infected with C. albicans. A previous study reports that the response of inflammatory expressions to lipopolysaccharide stimulation can be reduced in a mild acidic environment (pH 5.5−6.0) [42]. However, we did not analyze culture media pH produced by culturing probiotics over 24 h. A pH−mediated cytokines investigation might be needed to understand the interaction between pH and cytokine expression.
The diameters of the ZoIs reflect the antifungal efficacies of bacterial strains. Antimicrobial agents diffuse on the agar surface inoculated with C. albicans and inhibit its growth [43]. As we found in our results, use of an antimicrobial could be a convincing strategy to reduce the growth of C. albicans. However, Wilac D001 and lactobacillus spp. present a significant antifungal effect compared to disk only. Considering the disadvantage of the frequent use of antibiotics, such as the increase prevalence and incidence of VVC [44,45], alternative treatment with lactobacilli could be a promising long-term treatment without the development of antibiotic resistance.
There are still some limitations to this study. The antifungal ability of Wilac D001 against VVC was assessed only in vitro. Consequently, an in vivo experiment should be conducted prior to oral administration. Another limitation of this study is that the antifungal efficacy of Wilac D001 was not as pronounced as that of an antimicrobial agent. Nevertheless, the ZoI induced by Wilac D001 was comparable to that formed by L. reuteri and L. rhamnosus. Lastly, a single microbial was tested independently. Given that human microorganisms comprise numerous bacteria species, an experiment involving a combination with Lactobacillus species will be necessary, anticipating a synergistic effect.

5. Conclusions

Our findings suggest that Wilac D001 inhibits C. albicans growth by disrupting biofilm formation. Additionally, Wilac D001 suppresses the C. albicans-mediated upregulation of pro−inflammatory cytokines, including IL−6 and IL−8, in VECs. The antifungal effect of Wilac D001 is comparable to that of L. reuteri and L. rhamnosus. Therefore, Wilac D001 has an antifungal effect on VECs infected by C. albicans, especially by regulating pro−inflammatory cytokines. To investigate its efficacy as a health supplement, further in vivo studies will be needed.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/app14072676/s1, Figure S1: Gram staining of VECs adherent Wilac D001 under microscopy; Table S1: Culture conditions of microorganism.

Author Contributions

Conceptualization, G.L. and Y.-A.Y.; Methodology, A.A.; Software, S.P.; Validation, S.M.P. and A.A.; Formal Analysis, S.-M.K.; Investigation, G.L. and Y.-A.Y.; Resources, S.P., Y.M.H. and S.M.P.; Data Curation, Y.M.H. and S.P.; Writing—Original Draft Preparation, G.L.; Writing—Review & Editing, Y.-A.Y., G.L. and Y.-Y.G.; Visualization, A.A.; Supervision, Y.J.K.; Project Administration, Y.J.K.; Funding Acquisition, Y.J.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Basic Science Research Program through the National Research Foundation of Korea (NRF-2020R1I1A1A01071955, NRF-2020R1I1A1A01074518), BK21 FOUR (Fostering Outstanding Universities for Research) funded by the Ministry of Education (MOE, Korea), and the National Research Foundation of Korea (NRF-5199990614253, Education Research Center for 4IR-Based Health Care). This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2023-00266554).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article or Supplementary Material.

Conflicts of Interest

Author Sang min Park was employed by the company Pharmsville Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Yano, J.; Sobel, J.D.; Nyirjesy, P.; Sobel, R.; Williams, V.L.; Yu, Q.; Noverr, M.C.; Fidel, P.L. Current patient perspectives of vulvovaginal candidiasis: Incidence, symptoms, management and post-treatment outcomes. BMC Womens Health 2019, 19, 48. [Google Scholar] [CrossRef]
  2. Sobel, J.D.; Faro, S.; Force, R.W.; Foxman, B.; Ledger, W.J.; Nyirjesy, P.R.; Reed, B.D.; Summers, P.R. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am. J. Obstet. Gynecol. 1998, 178, 203–211. [Google Scholar] [CrossRef] [PubMed]
  3. Rodríguez-Cerdeira, C.; Gregorio, M.C.; Molares-Vila, A.; López-Barcenas, A.; Fabbrocini, G.; Bardhi, B.; Sinani, A.; Sánchez-Blanco, E.; Arenas-Guzmán, R.; Hernandez-Castro, R. Biofilms and vulvovaginal candidiasis. Colloids Surf. B Biointerfaces 2019, 174, 110–125. [Google Scholar] [CrossRef]
  4. Petrova, M.I.; Lievens, E.; Malik, S.; Imholz, N.; Lebeer, S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front. Physiol. 2015, 6, 81. [Google Scholar] [CrossRef]
  5. O’Hanlon, D.E.; Come, R.A.; Moench, T.R. Vaginal pH measured in vivo: Lactobacilli determine pH and lactic acid concentration. BMC Microbiol. 2019, 19, 13. [Google Scholar] [CrossRef]
  6. Xu, J.; Sobel, J.D. Antibiotic-associated vulvovaginal candidiasis. Curr. Infect. Dis. Rep. 2003, 5, 481–487. [Google Scholar] [CrossRef]
  7. Reed, B.D. Risk factors for Candida vulvovaginitis. Obstet. Gynecol. Surv. 1992, 47, 551–560. [Google Scholar] [CrossRef]
  8. De Gregorio, P.R.; Parolin, C.; Abruzzo, A.; Luppi, B.; Protti, M.; Mercolin, L.; Silva, J.A.; Giordani, B.; Marangoni, A.; Nader-Macías, M.E.F. Biosurfactant from vaginal Lactobacillus crispatus BC1 as a promising agent to interfere with Candida adhesion. Microb. Cell Factories 2020, 19, 133. [Google Scholar] [CrossRef]
  9. Bertarello, C.; Savio, D.; Morelli, L.; Bouzalov, S.; Davidova, D.; Bonetti, A. Efficacy and safety of Lactobacillus plantarum P 17630 strain soft vaginal capsule in vaginal candidiasis: A randomized non-inferiority clinical trial. Eur. Rev. Med. Pharmacol. Sci. 2024, 28, 384–391. [Google Scholar]
  10. De Vuyst, L.; Callewaert, R.; Crabbé, K. Primary metabolite kinetics of bacteriocin biosynthesis by Lactobacillus amylovorus and evidence for stimulation of bacteriocin production under unfavourable growth conditions. Microbiology 1996, 142, 817–827. [Google Scholar] [CrossRef]
  11. Amabebe, E.; Anumba, D.O. The vaginal microenvironment: The physiologic role of lactobacilli. Front. Med. 2018, 5, 181. [Google Scholar] [CrossRef]
  12. Manuzak, J.A.; Hensley-McBain, T.; Zevin, A.S.; Miller, C.; Cubas, R.; Agricola, B.; Gile, J.; Richert-Spuhler, L.; Patilea, G.; Estes, J.D.; et al. Enhancement of Microbiota in Healthy Macaques Results in Beneficial Modulation of Mucosal and Systemic Immune Function. J. Immunol. 2016, 196, 2401–2409. [Google Scholar] [CrossRef]
  13. Martinez, R.; Franceschini, S.A.; Patta, M.C.; Quintana, S.M.; Candido, R.C.; Ferreira, J.C.; De Martinis, E.C.P.; Reid, G. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett. Appl. Microbiol. 2009, 48, 269–274. [Google Scholar] [CrossRef]
  14. Chew, S.Y.; Cheah, Y.K.; Seow, H.F.; Sandai, D.; Than, L.T.L. Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 exhibit strong antifungal effects against vulvovaginal candidiasis-causing Candida glabrata isolates. J. Appl. Microbiol. 2015, 118, 1180–1190. [Google Scholar] [CrossRef]
  15. Köhler, G.A.; Assefa, S.; Reid, G. Probiotic Interference of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 with the Opportunistic Fungal Pathogen Candida albicans. Infect. Dis. Obstet. Gynecol. 2012, 2012, 636474. [Google Scholar] [CrossRef]
  16. Collins, M.D.; Samelis, J.; Metaxopoulos, J.; Wallbanks, S. Taxonomic studies on some leuconostoc-like organisms from fermented sausages: Description of a new genus Weissella for the Leuconostoc paramesenteroides group of species. J. Appl. Bacteriol. 1993, 75, 595–603. [Google Scholar] [CrossRef]
  17. Choi, I.-K.; Jung, S.-H.; Kim, B.-J.; Park, S.-Y.; Kim, J.; Han, H.-U. Novel Leuconostoc citreum starter culture system for the fermentation of kimchi, a fermented cabbage product. Antonie Van Leeuwenhoek 2003, 84, 247–253. [Google Scholar] [CrossRef]
  18. Park, S.M.; Mok, J.Y.; Cho, H.-R.; Song, I.-b.; Shin, Y.J.; Lee, K.b.; Lee, B.W.; Bae, M.-J. Effects of Weissella confusa Wilac D001 Isolated from Dandelion Kimchi on Dextran Sulphate Sodium-Induced Colitis in Mice. Food Suppl. Biomater. Health 2021, 1, e25. [Google Scholar] [CrossRef]
  19. Jin, H.; Jeong, Y.; Yoo, S.-H.; Johnston, T.V.; Ku, S.; Ji, G.E. Isolation and characterization of high exopolysaccharide-producing Weissella confusa VP30 from young children’s feces. Microb. Cell Factories 2019, 18, 110. [Google Scholar] [CrossRef] [PubMed]
  20. Lynch, K.M.; Lucid, A.; Arendt, E.K.; Sleator, R.D.; Lucey, B.; Coffey, A. Genomics of Weissella cibaria with an examination of its metabolic traits. Microbiology 2015, 161, 914–930. [Google Scholar] [CrossRef] [PubMed]
  21. You, Y.A.; Kwon, E.J.; Choi, S.J.; Hwang, H.S.; Choi, S.K.; Lee, S.M.; Kim, Y.J. Vaginal microbiome profiles of pregnant women in Korea using a 16S metagenomics approach. Am. J. Reprod. Immunol. 2019, 82, e13124. [Google Scholar] [CrossRef]
  22. Park, S.; Saravanakumar, K.; Sathiyaseelan, A.; Han, K.-S.; Lee, J.; Wang, M.-H. Polysaccharides of Weissella cibaria Act as a Prebiotic to Enhance the Probiotic Potential of Lactobacillus rhamnosus. Appl. Biochem. Biotechnol. 2023, 195, 3928–3940. [Google Scholar] [CrossRef]
  23. Lim, S.K.; Kwon, M.-S.; Lee, J.; Oh, Y.J.; Jang, J.-Y.; Lee, J.-H.; Park, H.W.; Nam, Y.-D.; Seo, M.-J.; Roh, S.W. Weissella cibaria WIKIM28 ameliorates atopic dermatitis-like skin lesions by inducing tolerogenic dendritic cells and regulatory T cells in BALB/c mice. Sci. Rep. 2017, 7, 40040. [Google Scholar] [CrossRef] [PubMed]
  24. Dumitru, R.; Hornby, J.M.; Nickerson, K.W. Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs. Antimicrob. Agents Chemother. 2004, 48, 2350–2354. [Google Scholar] [CrossRef] [PubMed]
  25. Osset, J.; Bartolome, R.M.; Garcia, E.; Andreu, A. Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J. Infect. Dis. 2001, 183, 485–491. [Google Scholar] [CrossRef] [PubMed]
  26. Naidu, A.S.; Chen, J.; Martinez, C.; Tulpinski, J.; Pal, B.K.; Fowler, R.S. Activated lactoferrin’s ability to inhibit Candida growth and block yeast adhesion to the vaginal epithelial monolayer. J. Reprod. Med. 2004, 49, 859–866. [Google Scholar] [PubMed]
  27. Zárate, G.; Nader-Macias, M. Influence of probiotic vaginal lactobacilli on in vitro adhesion of urogenital pathogens to vaginal epithelial cells. Lett. Appl. Microbiol. 2006, 43, 174–180. [Google Scholar] [CrossRef] [PubMed]
  28. Niu, X.-X.; Li, T.; Zhang, X.; Wang, S.-X.; Liu, Z.-H. Lactobacillus crispatus Modulates Vaginal Epithelial Cell Innate Response to Candida albicans. Chin. Med. J. 2017, 130, 273–279. [Google Scholar] [CrossRef] [PubMed]
  29. Matevosyan, L.; Bazukyan, I.; Trchounian, A. Antifungal and antibacterial effects of newly created lactic acid bacteria associations depending on cultivation media and duration of cultivation. BMC Microbiol. 2019, 19, 102. [Google Scholar] [CrossRef] [PubMed]
  30. Hočevar, K.; Maver, A.; Vidmar Šimic, M.; Hodžić, A.; Haslberger, A.; Premru Seršen, T.; Peterlin, B. Vaginal microbiome signature is associated with spontaneous preterm delivery. Front. Med. 2019, 6, 201. [Google Scholar] [CrossRef]
  31. Elizaldi, S.R.; Verma, A.; Walter, K.A.; Rolston, M.; Dinasarapu, A.R.; Durbin-Johnson, B.P.; Settles, M.; Kozlowski, P.A.; Raeman, R.; Iyer, S.S. Rectal microbiome composition correlates with humoral immunity to HIV-1 in vaccinated rhesus macaques. Msphere 2019, 4, e00824-00819. [Google Scholar] [CrossRef]
  32. Hummelen, R.; Vos, A.P.; van’t Land, B.; van Norren, K.; Reid, G. Altered host-microbe interaction in HIV: A target for intervention with pro- and prebiotics. Int. Rev. Immunol. 2010, 29, 485–513. [Google Scholar] [CrossRef]
  33. Cheaito, R.A.; Awar, G.; Alkozah, M.; Cheaito, M.A.; El Majzoub, I. Meningitis due to Weissella confusa. Am. J. Emerg. Med. 2020, 38, 1298.e1–1298.e3. [Google Scholar] [CrossRef]
  34. Cupi, D.; Elvig-Jørgensen, S.G. Safety assessment of Weissella confusa–A direct-fed microbial candidate. Regul. Toxicol. Pharmacol. 2019, 107, 104414. [Google Scholar] [CrossRef]
  35. Ahmed, S.; Singh, S.; Singh, V.; Roberts, K.D.; Zaidi, A.; Rodriguez-Palacios, A. The Weissella genus: Clinically treatable bacteria with antimicrobial/probiotic effects on inflammation and cancer. Microorganisms 2022, 10, 2427. [Google Scholar] [CrossRef]
  36. Fatmawati, N.N.D.; Gotoh, K.; Mayura, I.P.B.; Nocianitri, K.A.; Suwardana, G.N.R.; Komalasari, N.L.G.Y.; Ramona, Y.; Sakaguchi, M.; Matsushita, O.; Sujaya, I.N. Enhancement of intestinal epithelial barrier function by Weissella confusa F213 and Lactobacillus rhamnosus FBB81 probiotic candidates in an in vitro model of hydrogen peroxide-induced inflammatory bowel disease. BMC Res. Notes 2020, 13, 489. [Google Scholar] [CrossRef]
  37. Khan, F.; Bamunuarachchi, N.I.; Pham, D.T.N.; Tabassum, N.; Khan, M.S.A.; Kim, Y.-M. Mixed biofilms of pathogenic Candida-bacteria: Regulation mechanisms and treatment strategies. Crit. Rev. Microbiol. 2021, 47, 699–727. [Google Scholar] [CrossRef]
  38. Ahmad Khalili, A.; Ahmad, M.R. A review of cell adhesion studies for biomedical and biological applications. Int. J. Mol. Sci. 2015, 16, 18149–18184. [Google Scholar] [CrossRef]
  39. Coudeyras, S.; Jugie, G.; Vermerie, M.; Forestier, C. Adhesion of human probiotic Lactobacillus rhamnosus to cervical and vaginal cells and interaction with vaginosis-associated pathogens. Infect. Dis. Obstet. Gynecol. 2008, 2008, 549640. [Google Scholar] [CrossRef]
  40. Steele, C.; Fidel Jr, P.L. Cytokine and chemokine production by human oral and vaginal epithelial cells in response to Candida albicans. Infect. Immun. 2002, 70, 577–583. [Google Scholar] [CrossRef]
  41. Spear, G.T.; Zariffard, M.R.; Cohen, M.H.; Sha, B.E. Vaginal IL-8 levels are positively associated with Candida albicans and inversely with lactobacilli in HIV-infected women. J. Reprod. Immunol. 2008, 78, 76–79. [Google Scholar] [CrossRef] [PubMed]
  42. Hackett, A.; Trinick, R.; Rose, K.; Flanagan, B.; McNamara, P. Weakly acidic pH reduces inflammatory cytokine expression in airway epithelial cells. Respir. Res. 2016, 17, 82. [Google Scholar] [CrossRef] [PubMed]
  43. Balouiri, M.; Sadiki, M.; Ibnsouda, S.K. Methods for in vitro evaluating antimicrobial activity: A review. J. Pharm. Anal. 2016, 6, 71–79. [Google Scholar] [CrossRef]
  44. Xu, J.; Schwartz, K.; Bartoces, M.; Monsur, J.; Severson, R.K.; Sobel, J.D. Effect of Antibiotics on Vulvovaginal Candidiasis: A MetroNet Study. J. Am. Board. Fam. Med. 2008, 21, 261–268. [Google Scholar] [CrossRef]
  45. Hassanzadazar, H.; Ehsani, A.; Mardani, K.; Hesari, J. Investigation of antibacterial, acid and bile tolerance properties of lactobacilli isolated from Koozeh cheese. Proc. Vet. Res. Forum 2012, 3, 181–185. [Google Scholar]
Applsci 14 02676 g001
Figure 1. Morphological images of vaginal epithelial cells (VECs) and VECs infected by Candida albicans (C. albicans). (A) The microscopic images of monolayer VECs after VECs were 90–100% confluent for 96 h and (B) infectious VECs by 1 × 107 CFU of C. albicans. Black arrow indicates the aggregation of C. albicans. VECs = vaginal epithelial cells, C. albicans = Candida albicans, scale bar = 100 µm.
Figure 1. Morphological images of vaginal epithelial cells (VECs) and VECs infected by Candida albicans (C. albicans). (A) The microscopic images of monolayer VECs after VECs were 90–100% confluent for 96 h and (B) infectious VECs by 1 × 107 CFU of C. albicans. Black arrow indicates the aggregation of C. albicans. VECs = vaginal epithelial cells, C. albicans = Candida albicans, scale bar = 100 µm.
Applsci 14 02676 g001
Applsci 14 02676 g002
Figure 2. Wilac D001 prevented the attachment of C. albicans on VECs. (A) Competition assay indicated that Wilac D001 and C. albicans were inoculated for 1 h after VECs were 90–100% confluent for 96 h. (B) The percentage of adherent cells was determined in L. reuteri, L. rhamnosus, and Wilac-D001-treated VECs. The vaginal epithelial cells with (C) L. reuteri, (D) L. rhamnosus, and (E) Wilac D001 were cultured with C. albicans, respectively, and then Gram staining was performed. The black arrow indicates C. albicans, and red arrow indicates respective bacteria strains. Data were analyzed using a one-way analysis of variance (ANOVA). Bar graphs are expressed as mean ± SD. Scale bar = 50 µm. VECs: vaginal epithelial cells.
Figure 2. Wilac D001 prevented the attachment of C. albicans on VECs. (A) Competition assay indicated that Wilac D001 and C. albicans were inoculated for 1 h after VECs were 90–100% confluent for 96 h. (B) The percentage of adherent cells was determined in L. reuteri, L. rhamnosus, and Wilac-D001-treated VECs. The vaginal epithelial cells with (C) L. reuteri, (D) L. rhamnosus, and (E) Wilac D001 were cultured with C. albicans, respectively, and then Gram staining was performed. The black arrow indicates C. albicans, and red arrow indicates respective bacteria strains. Data were analyzed using a one-way analysis of variance (ANOVA). Bar graphs are expressed as mean ± SD. Scale bar = 50 µm. VECs: vaginal epithelial cells.
Applsci 14 02676 g002
Applsci 14 02676 g003
Figure 3. Wilac D001 reduced the expression levels of pro−inflammatory cytokines on infectious VECs with C. albicans. (A) Replacement assay showed that C. albicans and Wilac D001 were incubated serially on confluent VECs for ELISA assay. VECs were cultured with C. albicans in the presence or absence of Wilac D001, and the concentration of IL−6 and IL−8 was measured. Representative graphs show concentrations of IL−6 (B,D,F) and IL−8 (C,E,G) produced by VECs with Wilac D001 (B,C), L. reuteri (D,E), and L. rhamnosus (F,G). The results are described as Mean ± SD from triplicate experiments. VECs = vaginal epithelial cells, ELISA = enzyme-linked immunosorbent assay. Data were analyzed using a one-way analysis of variance (ANOVA) with Bonferroni’s post hoc correlation. NS: not significant. *: p-value < 0.05, **: p-value < 0.01, ***: p-value < 0.001. n = 3.
Figure 3. Wilac D001 reduced the expression levels of pro−inflammatory cytokines on infectious VECs with C. albicans. (A) Replacement assay showed that C. albicans and Wilac D001 were incubated serially on confluent VECs for ELISA assay. VECs were cultured with C. albicans in the presence or absence of Wilac D001, and the concentration of IL−6 and IL−8 was measured. Representative graphs show concentrations of IL−6 (B,D,F) and IL−8 (C,E,G) produced by VECs with Wilac D001 (B,C), L. reuteri (D,E), and L. rhamnosus (F,G). The results are described as Mean ± SD from triplicate experiments. VECs = vaginal epithelial cells, ELISA = enzyme-linked immunosorbent assay. Data were analyzed using a one-way analysis of variance (ANOVA) with Bonferroni’s post hoc correlation. NS: not significant. *: p-value < 0.05, **: p-value < 0.01, ***: p-value < 0.001. n = 3.
Applsci 14 02676 g003
Table 1. Diameters of the ZoI formed by Wilac D001 and all tested positive controls.
Table 1. Diameters of the ZoI formed by Wilac D001 and all tested positive controls.
NegativePositive ControlWilac D001
BlankSertaconazole NitrateL. rueteriL. rhamnosus
ZoI
(diameter, mm)		6.0 ± 0.018.3 ± 0.610.8 ± 0.3 *,#11.2 ± 0.3 *,#11.2 ± 0.3 *,#
The results are indicated as mean ± SD. Sertaconazole nitrate was used as the antimicrobial. ZoI: zone of inhibition. Data were analyzed using a one-way analysis of variance (ANOVA) with Bonferroni’s post hoc correlation. *: p < 0.001 compare with blank, #: p < 0.001 compare with Sertaconazole Nitrate, n = 3.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lee, G.; You, Y.-A.; Ansari, A.; Go, Y.-Y.; Park, S.; Hur, Y.M.; Kim, S.-M.; Park, S.M.; Kim, Y.J. The Antifungal Effect of Weissella confusa WIKIM51 (Wilac D001) on Vaginal Epithelial Cells Infected by Candida albicans. Appl. Sci. 2024, 14, 2676. https://doi.org/10.3390/app14072676

AMA Style

Lee G, You Y-A, Ansari A, Go Y-Y, Park S, Hur YM, Kim S-M, Park SM, Kim YJ. The Antifungal Effect of Weissella confusa WIKIM51 (Wilac D001) on Vaginal Epithelial Cells Infected by Candida albicans. Applied Sciences. 2024; 14(7):2676. https://doi.org/10.3390/app14072676

Chicago/Turabian Style

Lee, Gain, Young-Ah You, Abuzar Ansari, Yoon-Young Go, Sunwha Park, Young Min Hur, Soo-Min Kim, Sang Min Park, and Young Ju Kim. 2024. "The Antifungal Effect of Weissella confusa WIKIM51 (Wilac D001) on Vaginal Epithelial Cells Infected by Candida albicans" Applied Sciences 14, no. 7: 2676. https://doi.org/10.3390/app14072676

APA Style

Lee, G., You, Y.-A., Ansari, A., Go, Y.-Y., Park, S., Hur, Y. M., Kim, S.-M., Park, S. M., & Kim, Y. J. (2024). The Antifungal Effect of Weissella confusa WIKIM51 (Wilac D001) on Vaginal Epithelial Cells Infected by Candida albicans. Applied Sciences, 14(7), 2676. https://doi.org/10.3390/app14072676

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop